AgingResearch.News
Cardiovascular Drugs and Therapy

Candidate Residual Inflammatory Risk in HFpEF: A Multiorgan Framework for Longitudinal Phenotyping, Trial Enrichment, and Therapeutic Evidence Appraisal

By Zhaoqi Yan, Xiangyi Pu, Tiantian Ren, Show 6 more authorsRuxiu Liu
ReviewMechanisms
Paper

The paper

Zhaoqi Yan, Xiangyi Pu, Tiantian Ren, Show 6 more authorsRuxiu Liu

China Academy of Chinese Medical Sciences

Cardiovascular Drugs and Therapy, 27 Aug 2026

doi.org/10.1007/s10557-026-07941-zPubMed 42658386

Related